ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,321.41
      0.25%
      US Tech 100
      18,243.60
      0.26%
      Dow Jones
      39,872.99
      0.17%
      Brent Oil
      82.41
      -0.04%
      Bitcoin
      70,063.56
      -0.10%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Cellectar Biosciences Inc (CLRBZ)

      7. Cellectar Biosciences Inc (CLRBZ) News

      CLRBZ

      Cellectar Biosciences (CLRBZ)

      Cellectar Biosciences Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CLRBZ
      DateTimeSourceHeadlineSymbolCompany
      01/07/20198:30AMGlobeNewswire Inc.Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple MyelomaNASDAQ:CLRBZCellectar Biosciences Inc
      01/03/20198:30AMGlobeNewswire Inc.Cellectar Biosciences to Present at the Biotech ShowcaseNASDAQ:CLRBZCellectar Biosciences Inc
      12/11/20188:30AMGlobeNewswire Inc.Cellectar Granted Japanese Patent for CLR 131NASDAQ:CLRBZCellectar Biosciences Inc
      12/04/20188:30AMGlobeNewswire Inc.Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple MyelomaNASDAQ:CLRBZCellectar Biosciences Inc
      11/13/20188:30AMGlobeNewswire Inc.Cellectar Reports Third Quarter 2018 Financial Results and Provides Business UpdateNASDAQ:CLRBZCellectar Biosciences Inc
      11/12/20188:30AMGlobeNewswire Inc.Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology StudiesNASDAQ:CLRBZCellectar Biosciences Inc
      10/02/20188:00AMGlobeNewswire Inc.Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myelo...NASDAQ:CLRBZCellectar Biosciences Inc
      09/27/20188:30AMGlobeNewswire Inc.Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare ConferenceNASDAQ:CLRBZCellectar Biosciences Inc
      09/25/20188:30AMGlobeNewswire Inc.Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric OsteosarcomaNASDAQ:CLRBZCellectar Biosciences Inc
      09/24/20188:00AMGlobeNewswire Inc.Cellectar Biosciences Provides an Update on the FDA Import AlertNASDAQ:CLRBZCellectar Biosciences Inc
      09/17/20188:30AMGlobeNewswire Inc.FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of OsteosarcomaNASDAQ:CLRBZCellectar Biosciences Inc
      08/29/20188:30AMGlobeNewswire Inc.Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment ConferenceNASDAQ:CLRBZCellectar Biosciences Inc
      08/20/20188:30AMGlobeNewswire Inc.Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma PatientsNASDAQ:CLRBZCellectar Biosciences Inc
      08/13/20188:00AMGlobeNewswire Inc.Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s SarcomaNASDAQ:CLRBZCellectar Biosciences Inc
      08/10/20188:00AMGlobeNewswire Inc.Cellectar Reports 2018 Second Quarter Financial Results and Provides Business UpdateNASDAQ:CLRBZCellectar Biosciences Inc
      08/01/20188:30AMGlobeNewswire Inc.Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug ConjugateNASDAQ:CLRBZCellectar Biosciences Inc
      07/31/20184:05PMGlobeNewswire Inc.Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Op...NASDAQ:CLRBZCellectar Biosciences Inc
      07/27/20188:30AMGlobeNewswire Inc.Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering NASDAQ:CLRBZCellectar Biosciences Inc
      07/18/20188:00AMGlobeNewswire Inc.Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL PatientsNASDAQ:CLRBZCellectar Biosciences Inc
      07/17/20188:00AMGlobeNewswire Inc.Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical ...NASDAQ:CLRBZCellectar Biosciences Inc
      07/13/20184:05PMGlobeNewswire Inc.Cellectar Announces 1-for-10 Reverse Stock SplitNASDAQ:CLRBZCellectar Biosciences Inc
      07/09/20188:00AMGlobeNewswire Inc.Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s SarcomaNASDAQ:CLRBZCellectar Biosciences Inc
      06/28/20188:00AMGlobeNewswire Inc.Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 TrialNASDAQ:CLRBZCellectar Biosciences Inc
      06/07/20188:30AMGlobeNewswire Inc.Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131NASDAQ:CLRBZCellectar Biosciences Inc
      06/06/20188:00AMGlobeNewswire Inc.FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of RhabdomyosarcomaNASDAQ:CLRBZCellectar Biosciences Inc
      05/11/20188:00AMGlobeNewswire Inc.Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial ResultsNASDAQ:CLRBZCellectar Biosciences Inc
      05/09/20182:28PMGlobeNewswire Inc.Cellectar Granted Orphan Drug Designation for CLR 131 to Treat RhabdomyosarcomaNASDAQ:CLRBZCellectar Biosciences Inc
      05/02/20188:00AMGlobeNewswire Inc.Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat NeuroblastomaNASDAQ:CLRBZCellectar Biosciences Inc
      04/17/20188:00AMGlobeNewswire Inc.Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Mu...NASDAQ:CLRBZCellectar Biosciences Inc
      04/16/20188:05AMGlobeNewswire Inc.Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broa...NASDAQ:CLRBZCellectar Biosciences Inc
       Showing the most relevant articles for your search:NASDAQ:CLRBZ